Diabetes News and Research

Latest Diabetes News and Research

New treatment for vaso-occlusive crisis in sickle cell patients

GlycoMimetics, Inc. (GMI), a clinical-stage biotechnology company that is developing a new class of glycobiology-based therapies for a broad range of indications, today announced that a pilot study of the company’s lead candidate, GMI-1070, is underway in sickle cell patients. The first patients in this pilot study were treated at Children’s Hospital & Research Center Oakland in California.

4 Sep 2009

Type 2 diabetic people not consuming healthy diets

People with type 2 diabetes are not consuming sufficiently healthy diets and could benefit from ongoing nutritional education and counseling, according to a new study by researchers at Wake Forest University School of Medicine and colleagues.

4 Sep 2009

H1N1 vaccine to cost countries $2.50 - $20 per dose

The H1N1 (swine) flu vaccine will cost countries between $2.50 and $20 per dose, based on their ability to pay, according to the director of the Initiative for Vaccine Research at the WHO, Marie-Paule Kieny, Agence France-Presse/Khaleej Times reports. During an interview published in the September issue of the WHO Bulletin, Kieny "also warned that there would not be enough vaccines for the world's population and that people should not rely entirely on the vaccine," the news service writes (9/2).

3 Sep 2009

Reliable and relevant information needed to rein in the costs of federal health-care programs, says study

For economists and policy-makers to understand the true value of the costs and savings of preventive health programs for chronic disease, the Congressional Budget Office (CBO) should incorporate long-term clinical outcomes data and look beyond the 10-year window when making cost estimates, says a team of University of Chicago researchers in today's issue of Health Affairs.

3 Sep 2009

Medtronic's COPE-HCV clinical study commences

Medtronic, Inc., today reported the initiation and first enrollments of patients in COPE-HCV (COntinuous Interferon Delivery via the Medtronic Paradigm Pump Infusion System Clinical Evaluation for Chronic HCV), the company’s first-ever clinical study using an external pump infusion system to treat patients with the hepatitis C virus (HCV).

3 Sep 2009

Low HDL-cholesterol and high triglycerides linked to increased risk of CHD

Low levels of high-density lipoprotein cholesterol (HDL-C) and raised triglycerides, affecting millions of patients worldwide, are strongly linked to significantly increased risk of coronary heart disease (CHD) even in patients who achieve or surpass current low density lipoprotein cholesterol (LDL-C) targets.

3 Sep 2009

Health Information Resource Center recognizes SHPS, presents nine awards

SHPS, a leading provider of health improvement and health benefits solutions, received nine awards for its healthcare communications in the 2009 National Health Information Awards(SM) program.

3 Sep 2009

Green to Grow calls for support of the California Toxics-Free Babies and Toddlers Act

Green to Grow (www.greentogrow.com), a leading Los Angeles-based manufacturer of BPA-free baby bottles that provide a safe alternative to polycarbonate products containing Bisphenol A (BPA) - a chemical currently banned in Canada, Minnesota, Connecticut and under scrutiny in several European nations - is urging the public and California Assembly members to support the Toxics-Free Babies and Toddlers Act (SB 797).

3 Sep 2009

FDA extends review period for Endo Pharmaceuticals' testosterone undecanoate

Endo Pharmaceuticals announced today that it has been informed by the U.S. Food and Drug Administration (FDA) that the agency has extended its review period for its long-acting testosterone undecanoate injection for men diagnosed with hypogonadism, from Sept. 2, 2009 to Dec. 2, 2009.

3 Sep 2009

Study identifies key compound that quickens recovery from life-threatening blood cell shortages

A key compound resupplies bone marrow with fast-acting stem cells that can more quickly rekindle blood cell production, according to a study published online today in the journal Blood. While the study was in mice, in the study authors say it has the potential to increase survival among patients with life-threatening blood cell shortages.

3 Sep 2009

NetBase Solutions launches healthBase Content Intelligence platform

NetBase Solutions, Inc. today launched healthBase (healthbase.netbase.com), a public showcase of NetBase's Content Intelligence platform, which is able to read sentences inside documents, linguistically understand the meaning and power breakthrough search and discovery solutions.

3 Sep 2009

Strelitz Diabetes Center awarded a two-year grant for 12-LO research

Scientists at Eastern Virginia Medical School's Strelitz Diabetes Center have been awarded a two-year grant totaling $472,683 by the Juvenile Diabetes Research Foundation (JDRF).

3 Sep 2009

New device for treating hypoglycemia launched globally

At this year’s annual meeting of the International Society for Pediatric and Adolescent Diabetes (ISPAD) in Ljubljana, Slovenia, Medtronic, Inc. announced the global launch of a novel technology designed to provide additional protection against the risks associated with hypoglycemia.

3 Sep 2009

Researchers to analyse nanoparticles

Researchers at Swansea University's Centre for NanoHealth have been awarded £1 million by the Research Councils' Nanoscience through Engineering to Application cross-council programme, led by the Engineering and Physical Science Research Council (EPSRC), to analyse the levels at which nanoparticles can be deemed safe within cells.

3 Sep 2009

Increase in Rifampicin dosage shortens tuberculosis treatment duration

According to Dutch researcher Hanneke Later-Nijland, it may be possible to shorten the duration of treatment for tuberculosis. Due to the long duration of treatment, not every patient sees it through. Partly because of this, tuberculosis is one of the most lethal diseases in developing countries.

3 Sep 2009

Sepracor to be acquired by Dainippon Sumitomo Pharma for $2.6 billion

Dainippon Sumitomo Pharma Co., Ltd. (“DSP”, TSE: 4506) and Sepracor Inc. (“Sepracor”, Nasdaq: SEPR) today announced that they have entered into a definitive agreement pursuant to which DSP will acquire Sepracor for approximately $2.6 billion through a cash tender offer of $23.00 per share, followed by a merger to acquire all remaining outstanding Sepracor shares at the same price paid in the tender offer.

3 Sep 2009

Alloantigen-specific Treg cells targeted for organ transplantation

An increased understanding of the role of the body's immune system in the development of diseases such as prostate cancer, squamous cell carcinoma (a type of skin cancer), type 1 diabetes, autoimmune liver disease, and in the rejection of transplanted organs by some transplant patients, has paved the way for a pioneering research programme which aims to develop 'enhanced' cells as therapies.

3 Sep 2009

New target for cancer cure identified

Researchers Dr. Marc Therrien at the Institute for Research in Immunology and Cancer (IRIC) of the Universit- de Montr-al, and Dr. Frank Sicheri, at the Samuel Lunenfeld Research Institute of Mount Sinai Hospital in Toronto, have discovered a new target that may be instrumental in the development of new, more effective cancer therapies.

3 Sep 2009

New method for treating hand disorder discovered

Researchers in the Department of Orthopaedics at Stony Brook University Medical Center have developed an injectable form of the enzyme, collagenase, that significantly improves outcomes of Dupuytren's contracture (or disease), a debilitating disorder caused by progressive accumulation of collagen that deforms fingers and limits motion. Reported in September 3, 2009, issue of The New England Journal of Medicine, the study involved treatment of 308 patients with Duputren's disease in 16 sites nationwide. The results indicate that the injections are safe and effective.

3 Sep 2009

Pacific Biometrics enters into a Loan and Security Agreement to raise $4 million

Pacific Biometrics, Inc. (OTC Bulletin Board: PBME), a leading provider of specialized reference laboratory and contract research services, today announced the Company's entry into a Loan and Security Agreement with Terry M. Giles, providing for a $4 million loan (the "Loan") to the Company.

2 Sep 2009